Jim Cramer's Lightning Round: Recursion Pharmaceuticals & NuScale Power Stock Analysis

Recursion Pharmaceuticals Stock Analysis

• 📈 Ron from California expresses frustration with Recursion Pharmaceuticals due to its consistent stock drops despite positive earnings.
• 💡 Ron believes the stock will turn around due to $30 million in funding, $785 million in cash, and a favorable drug trial announcement expected on December 8th.
• 🧠 The appointment of Nat Khan, described as a genius, to lead Recursion Pharmaceuticals on January 1st is seen as a positive catalyst, with 2026 projected to be a banner year.
• 🤔 Jim Cramer acknowledges the stock's horrendous performance and states he doesn't like recommending such stocks, categorizing it as speculative.
• ⚠️ Cramer advises that it's only suitable for investors willing to take the pain associated with its volatility.

NuScale Power Stock Analysis

• 💬 Mark from New Jersey inquires about NuScale Power SMR (Small Modular Reactor) stock, asking whether to buy, hold, or sell.
• ❌ Cramer's only buy recommendation in the nuclear sector is GE Vernova, stating they are the only ones who know how to build these reactors.
• 📉 Cramer advises Mark to scale out of NuScale Power on the way up, suggesting selling portions at $23, $25, and $27, and exiting completely at $30.